Introduction
============

Cesarean section (CS) is the most commonly performed surgery worldwide with a global rise of CS rate across different countries. In Egypt, the rate of CS is about 52% of all deliveries according to the latest reports.[@b1-ijwh-11-023] CS is not a complication-free operation but linked to some short-term and long-term complications such as infection, bleeding, trauma to adjacent organs, peripartum hysterectomy, and anesthetic problems.[@b2-ijwh-11-023] A lot of modifications in the surgical steps were introduced to minimize these perioperative complications.[@b3-ijwh-11-023]

One of the assessed procedures during CS was mechanical dilatation of the cervix in elective cases.[@b4-ijwh-11-023],[@b5-ijwh-11-023] In 2011, a Cochrane systematic review had assessed the effects of mechanical dilatation of the cervix on postoperative morbidity and specified postpartum hemorrhage (PPH) as primary outcome measure.[@b6-ijwh-11-023] They concluded that cervical dilatation had not significantly improved the postpartum outcomes and recommend further studies for evaluating its effect on reducing the postoperative morbidity.[@b7-ijwh-11-023]

Evaluation of CS scar integrity before next pregnancy became feasible due to improvements in imaging modalities that have facilitated the evaluation of CS scars.[@b7-ijwh-11-023] CS scar defects appear as a wedge-shaped cystic or hypoechoic distortion in the scar in the nonpregnant uterus.[@b8-ijwh-11-023] Hysterosalpingography was the first modality that described the CS scar;[@b9-ijwh-11-023] then trans-abdominal (TAS) and transvaginal (TVS) ultrasound were used for the evaluation of the scar.[@b10-ijwh-11-023],[@b11-ijwh-11-023] Nowadays, three-dimensional (3D) TAS and TVS were also incorporated in the evaluation of the lower uterine segment (LUS) and scar integrity especially during pregnancy.[@b12-ijwh-11-023],[@b13-ijwh-11-023]

Therefore, the current study was designed to evaluate the impact of mechanical cervical dilatation during elective CS on postpartum infectious morbidity and the scar integrity at 6 months post operation. To our knowledge, this is the first study reported in the literature to evaluate the scar integrity in nonpregnant women after mechanical cervical dilatation during elective CS.

Materials and methods
=====================

Study type, setting, and duration
---------------------------------

The current study was a randomized double-blind clinical trial registered in UMIN-CTR (UMIN000027946) conducted at a tertiary university hospital in the period between July 1, 2017 and April 30, 2018. This study was approved by the local ethics committee of Tanta University with the code of 31677/6/17. The study was conducted in accordance with the Declaration of Helsinki, and all participants signed a written informed consent before inclusion in the study.

Study participants
------------------

All pregnant women scheduled for elective CS under spinal anesthesia were invited to participate in the study. We included pregnant women with a singleton fetus at term ≥37 weeks of gestation, with American Society of Anesthesiology physical status I or II. We excluded patients with multiple gestation, placenta previa, premature rupture of membranes, and chorioamnionitis. In addition, those with pre-eclampsia, diabetes mellitus, current or previous history of heart disease, liver, renal disorders, or known coagulopathy were excluded from the study. The recruited women were assessed preoperatively through history taking with regard to age, parity, gestational age, and body mass index measurement.

Sample size calculation
-----------------------

The average number of total deliveries at Tanta University hospitals was determined to be 3,500 per year.[@b14-ijwh-11-023] Postulating that cervical dilatation (H~0~) yields better postoperative outcomes and correlated to good quality scars. Using 95% confidence level, 80% power, and 50% to calculate the appropriate sample size, 346 women were estimated to be included in the study. The enrolled patients were higher than this sample size owing to loss of large numbers in follow-up periods (Epi-info: Centers for Disease Control and Prevention, Atlanta, GA, USA).

Randomization
-------------

A statistician prepared a computer-generated random table and placed the group allocation in serially numbered closed opaque envelopes in a 1:1 ratio. The envelopes were opened only by the obstetrician just before CS. Patients were allocated to either study group (cervical dilatation) or control group (no cervical dilatation). Allocation was never changed after opening the envelopes. All patients were blinded to the allocation to avoid bias.

Intervention
------------

Eligible participants were allocated to one of the two groups: Study group (women with intraoperative cervical dilatation) and control group (women with no intraoperative cervical dilatation). Cervical dilatation was carried out by inserting Hegar's dilator no. 6 into the cervical canal after removal of the placenta and membranes from upward to downward direction.

All CSs were carried out by the same team of study investigators under spinal anesthesia, using a 25-gauge needle to inject 0.5 mg morphine and 12 mg 0.5% bupivacaine. The technique of CS was the same in all women through Pfannenstiel incision of the skin. Then, vaginae of all women were cleaned with povidone iodine solution immediately before CS. The suture materials were the same in all cases. All patients received 2 g of cephradine for perioperative prophylaxis after umbilical cord clamping.

The uterine incision was closed with a continuous two layers of Vicryl 0. The visceral peritoneum was unsutured while the parietal peritoneum was closed with Vicryl 2-0. The rectus sheath was closed with a continuous single layer of Vicryl 1. Lastly, the skin was closed by subcuticular Vicryl 2-0. All suture materials were developed by Ethicon (Somerville, NJ, USA).

Follow-up
---------

Postoperative care was the same for both the groups. They received intravenous fluids (ringer lactate and 5% glucose) at the rate of 100 mL/h then oral clear fluids were started 6 hours postoperatively. Urinary Foley catheters were removed at 12 hours post operation. The duration of hospital stay was calculated from the day of CS until discharge from the hospital. Cases with febrile morbidity, defined as a persistent fever of at least 38°C for at least 24 hours after surgery not associated with lower abdominal or pelvic tenderness, were recorded.

All women were asked to attend our outpatient clinic 1 week after CS for the assessment of the skin incision and uterine cavity to exclude wound infection and endometritis. Wound infection was diagnosed if purulent discharge from the incision, swelling, erythema, induration, or wound breakdown was present. Endometritis was diagnosed if there is postoperative fever (\>38°C after the first postoperative day) with uterine tenderness, foul smelling lochia, and leukocytosis (white cell count \>15,000/mL). The second follow-up visit was at 6 weeks postpartum for the initiation of family planning method. Uterine subinvolution was assessed in this visit, defined as delayed or absent involution of the uterus during the postpartum period.

The patients were given a follow-up card to be evaluated 6 months after CS by 3D ultrasonography to check for scar integrity and quality. Scar evaluation was assessed by measuring the scar width, scar depth, thickness of the residual myometrial tissue (RMT), vascularity, and integrity (presence or absence of defects). Cesarean scars were assessed by 3D-TVS using Voluson E8 machine (GE healthcare, USA). All ultrasound examinations were carried out by the same investigator who was an expert level II sonographer. The sonographer was blinded to the allocated group of the patients.

Study outcomes
--------------

The primary outcome of the study was the difference in sonographic parameters of scar integrity between the two groups as evaluated 6 months post operation. The secondary outcomes included the duration of hospital stay, the rate of febrile morbidity, uterine subinvolution, wound infection, and endometritis.

Statistical analysis
--------------------

The data were collected and entered into a Microsoft Access database and then analyzed using the Statistical Package for Social Science (version 22; IBM Corporation, Armonk, NY, USA). Quantitative variables were presented in terms of mean and standard deviation. They were compared using Student's *t*-test. Qualitative variables were presented as frequency and percentage. Chi-squared test was used for comparison between groups. For analysis, *P*\<0.05 was considered to be significant.

Results
=======

Four hundred twenty-two women were approached to participate in the study. We excluded 16 cases as they did not meet the inclusion criteria and six women refused to participate in the study. The remaining 400 women were randomized to either of the study groups (200 women in each arm). Forty-one women in the study group and 37 women in the control group were excluded from the final analysis as they were lost to follow-up at 6 months ([Figure 1](#f1-ijwh-11-023){ref-type="fig"}). No statistical significant difference were found regarding the baseline characteristics of both the groups ([Table 1](#t1-ijwh-11-023){ref-type="table"}).

[Table 2](#t2-ijwh-11-023){ref-type="table"} demonstrates the outcomes of the study. In the postpartum period, there was no significant difference regarding the rate of wound infection or endometritis in both the groups (*P*=0.717 and 0.227, respectively). The incidence of febrile morbidity was higher in the no cervical dilatation group (10.5%) compared to the cervical dilatation group (5.0%) (*P*=0.045). A significant difference was noticed regarding the rate of subinvolution which was higher in no cervical dilatation group (*P*=0.012). In addition, the duration of hospital stay was significantly higher in the no cervical dilatation group (*P*=0.001).

The results of ultrasonographic scar assessment were shown in [Table 3](#t3-ijwh-11-023){ref-type="table"}. Scar width, depth were significantly higher in the cervical dilatation group than in control group (*P*=0.002 and 0.001, respectively). Fewer cases with scar defects (niche) were found in the cervical dilatation group than in the control group (5.03% vs 11.04%, respectively, *P*=0.048) as shown in [Figure 2](#f2-ijwh-11-023){ref-type="fig"}. Even the RMT was thicker in the cervical dilatation group than the control group (6.5±1.4 vs 4.7±2.3 mm, respectively, *P*=0.002) as shown in [Figures 3](#f3-ijwh-11-023){ref-type="fig"} and [4](#f4-ijwh-11-023){ref-type="fig"}. Scars in the study group were more vascular than in the control group (*P*=0.002).

Discussion
==========

In the present study, we found that mechanical cervical dilatation during elective CS is associated with reduced rate of febrile morbidity, uterine subinvolution, and duration of hospital stay with no effect on the rates of wound infection and endometritis. Moreover, the scar integrity and vascularity 6 months postpartum was significantly better with cervical dilatation.

The efficacy of mechanical cervical dilatation during elective CS is still debatable. Previous studies conducted to assess the surgical outcomes and postpartum maternal health had equivocal conclusions that dilatation of the cervix is not associated with improved surgical outcomes.[@b6-ijwh-11-023] Evidence failed to support the occurrence of infectious morbidity in patients with cervical dilatation during elective CS.[@b6-ijwh-11-023] This could be attributed to the difference in primary and secondary outcomes, small sample size, and variable methods of evaluation of the study outcomes.

The rationale to dilate the cervix during elective CS was allowance of more drainage of blood and products of conception through the dilated cervix. Retained blood may distend the LUS with subsequent atony, PPH, and further need for blood transfusion. Moreover, retention of blood in the LUS increases postoperative pain and stretches the cesarean scar leading to defective scar integrity that could predispose to scar ectopic pregnancy or uterine rupture in the future pregnancies.[@b15-ijwh-11-023] The opposite rationale for cervical dilatation was increasing the risk of contamination of uterine and abdominal wounds with vaginal infections if cervical dilatation was performed.[@b16-ijwh-11-023]

Regarding infectious morbidity, we found no significant differences regarding endometritis or wound sepsis between the two groups. We speculated that febrile morbidity was higher in the non-dilated cervix group owing to retained blood in the LUS. Our results were similar to most of the previous studies in these outcomes.[@b4-ijwh-11-023],[@b17-ijwh-11-023]--[@b22-ijwh-11-023]

Ahmed et al conducted a clinical trial to evaluate the effect of routine cervical dilatation during elective CS on maternal morbidity on 131 patients. They found that cervical dilatation did not reduce the risk of postoperative maternal fever or wound infection.[@b5-ijwh-11-023] Tosun et al conducted a randomized trial to investigate the necessity of cervical dilation in elective CS on 150 patients. They found similar results as previous studies, but the only difference was that the endometrial thickness was more in non-dilated cervix group than in dilated cervix group (9.51±3.35 vs 6.87±2.50 mm). They explained that thick endometrial cavity may be due to presence of retained fluid and blood in the uterine cavity, increasing the occurrence of hematometra.[@b17-ijwh-11-023] Similar results regarding endometrial thickness were obtained by Sakinci et al.[@b21-ijwh-11-023]

Recently, Kirscht et al conducted a randomized controlled study (Dondi Trial) on 447 patients to assess the effects of cervical dilatation on postoperative morbidity. They found no significant difference in infectious morbidity between the two groups. The only difference reported was that the retained products of conception were nil in the dilatation group compared to 6.2% in the no dilatation group (*P*\<0.001).[@b20-ijwh-11-023]

One of the aims of the current study is to assess the effect of cervical dilatation on the scar vascularity and integrity. The scar was assessed after 6 months of CS to allow for complete healing and return of regional anatomy to pre-pregnancy state. One study approved that scar could be assessed readily at 6 weeks.[@b23-ijwh-11-023] Other studies have assessed the scar at 3 months or at 6 months to ensure the scar edema has resolved and complete healing had occurred.[@b7-ijwh-11-023],[@b24-ijwh-11-023]--[@b26-ijwh-11-023]

The current study is considered the first one to assess the effect of cervical dilation on the cesarean scar quality and integrity. Scar width, depth, and location were significantly higher in dilatation group. Moreover, fewer cases of scar defects were noticed in the dilatation group than in no dilatation group (5.03% vs 11.04%, respectively). The RMT in the scar defect was thicker in the dilatation group (*P*=0.002). The color Doppler examination revealed more vascularization of scar in the dilatation group (*P*=0.002). The explanation for these findings may be the stretching of the LUS and distention by retained blood leading to weak scar and poor healing with subsequent more scar defects and thin scars.

The strengths of our study include that it was a randomized clinical trial. In addition, all CSs were carried out by the same team using the same surgical steps and type of anesthesia was standardized. Limitations included the inability to calculate the ideal sample size according to the primary outcome as no previous studies had assessed the scar integrity after cervical dilatation.

Conclusion
==========

Cervical dilatation during elective CS was safe and not associated with increase in postoperative infectious morbidity regarding endometritis or wound sepsis. Scar evaluation revealed that cervical dilatation yields thick scars with low incidence of scar defects.

Data sharing
============

The authors do not intend to share individual de-identified participant data.
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![RMT assessment by 3D ultrasound in cervical dilatation group.\
**Abbreviations:** CS, cesarean section; RMT, residual myometrial tissue; CX, cervix.](ijwh-11-023Fig4){#f4-ijwh-11-023}

###### 

The baseline characteristics of the study participants

  Variables                                                            Cervical dilatation (n=200)   No cervical dilatation (n=200)   *P*-value
  -------------------------------------------------------------------- ----------------------------- -------------------------------- -----------
                                                                                                                                      
  Age (years)[a](#tfn1-ijwh-11-023){ref-type="table-fn"}               29.45±6.58                    29.20±6.30                       0.727
  Parity[a](#tfn1-ijwh-11-023){ref-type="table-fn"}                    2.60±1.74                     2.48±1.61                        0.521
  Maternal BMI (kg/m^2^)[a](#tfn1-ijwh-11-023){ref-type="table-fn"}    25.9±4.63                     26.3±4.55                        0.434
  Gestational age (weeks)[a](#tfn1-ijwh-11-023){ref-type="table-fn"}   38.18±1.12                    38.15±1.11                       0.809
  No of previous CS[b](#tfn2-ijwh-11-023){ref-type="table-fn"}                                                                        
  No CS                                                                75 (37.5)                     73 (36.5)                        0.668
  One CS                                                               82 (41.0)                     76 (38.0)                        
  Two CS                                                               27 (13.5)                     30 (15.0)                        
  Three or more CS                                                     16 (8.0)                      21 (10.5)                        

**Notes:**

Data are presented as mean ± SD and compared using Student's *t*-test.

Data are presented as frequency (percentage) and compared using chi-squared test. **Abbreviations:** BMI, body mass index; CS, cesarean section.

###### 

The rate of infectious morbidity in both the study groups after CS

  Variables                                                                     Cervical dilatation   No cervical dilatation   *P*-value
  ----------------------------------------------------------------------------- --------------------- ------------------------ --------------------------------------------------
  Febrile morbidity[a](#tfn3-ijwh-11-023){ref-type="table-fn"}                  10 (5.0)              21 (10.5)                0.045[b](#tfn4-ijwh-11-023){ref-type="table-fn"}
  Wound infection[a](#tfn3-ijwh-11-023){ref-type="table-fn"}                    11 (5.5)              13 (6.5)                 0.717
  Endometritis[a](#tfn3-ijwh-11-023){ref-type="table-fn"}                       3 (1.5)               2 (1.0)                  0.227
  Uterine subinvolution[a](#tfn3-ijwh-11-023){ref-type="table-fn"}              2 (1.0)               11 (5.5)                 0.012[b](#tfn4-ijwh-11-023){ref-type="table-fn"}
  Duration of hospital stay (days)[c](#tfn5-ijwh-11-023){ref-type="table-fn"}   4.17±1.10             4.77±1.17                0.001[b](#tfn4-ijwh-11-023){ref-type="table-fn"}

**Notes:**

Data are presented as frequency (percentage) and compared using chi-squared test.

Statistical significant difference.

Data are presented as mean ± SD and compared using Student's *t*-test.

**Abbreviation:** CS, cesarean section.

###### 

The results of ultrasonographic scar assessment in both the study groups 6 months after CS

  Variables                                                                        Cervical dilatation (n=159)   No cervical dilatation (n=163)   *P*-value
  -------------------------------------------------------------------------------- ----------------------------- -------------------------------- ---------------------------------------------------
  Scar width (mm)[a](#tfn7-ijwh-11-023){ref-type="table-fn"}                       23.48±5.70                    21.40±3.88                       0.002[b](#tfn8-ijwh-11-023){ref-type="table-fn"}
  Scar depth (mm)[a](#tfn7-ijwh-11-023){ref-type="table-fn"}                       11.58±0.92                    9.88±0.56                        0.0001[b](#tfn8-ijwh-11-023){ref-type="table-fn"}
  Scar distance from internal os (mm)[a](#tfn7-ijwh-11-023){ref-type="table-fn"}   9.5±1.7                       8.8±1.3                          0.0001[b](#tfn8-ijwh-11-023){ref-type="table-fn"}
  Scar defect (niche)[c](#tfn9-ijwh-11-023){ref-type="table-fn"}                   8 (5.03)                      18 (11.04)                       0.048[b](#tfn8-ijwh-11-023){ref-type="table-fn"}
  Residual MT in niche cases (mm)[a](#tfn7-ijwh-11-023){ref-type="table-fn"}       6.5±1.4                       4.7±2.3                          0.002[b](#tfn8-ijwh-11-023){ref-type="table-fn"}
  Scar vascularity^c^ Hyper-vascular Hypo-vascular                                 56 (35.22) 103 (64.78)        33 (20.25) 130 (79.75)           0.002[b](#tfn8-ijwh-11-023){ref-type="table-fn"}

**Notes:**

Data are presented as mean ± SD and compared using Student's *t*-test.

Statistical significant difference.

Data are presented as frequency (percentage) and compared using chi-squared test.

**Abbreviations:** MT, myometrial thickness; CS, cesarean section.
